

Ovarian Cancer: *BRCA* Genetics Reveals Targets for New Therapies

Grazia Artioli^{1*}, Lucia Borgato¹, Simonetta Ausoni^{2#} and Giuseppe Azzarello¹

¹Department of Medical Sciences - Oncology and Hematology Unit, Mirano Hospital, 30033 Mirano (Venice), Italy

²Department of Biomedical Sciences, University of Padua, 35121 Padua, Italy

[#]These authors contributed equally

Abstract

Ovarian cancer is the most lethal gynecological malignancy and the fifth cause of cancer mortality in women in the Western Countries. Advanced genomic analysis showed that most hereditary and a large proportion of sporadic ovarian cancers are associated with genetic and epigenetic aberrations either in *BRCA1* and/or *BRCA2* genes or in other genes involved in DNA repair and genomic stability. *BRCA* dysfunction identifies a major subset of ovarian cancers with peculiar epidemiological and clinical features, such as higher incidence in younger females, high-grade serous phenotype, better chemosensitivity and outcome. Being particularly sensitive to DNA-damaging agents, such as platinum compounds, these tumors are suitable for new therapeutic options that represent future challenges for oncologists. In this article we review the known molecular dysfunction in hereditary ovarian cancers and *BRCA*ness and discuss the implications of new advances for more personalized treatments.

Keywords: Ovarian Cancer (OC); *BRCA1*; *BRCA2*; *BRCA*ness; Synthetic lethality; Platinum-based chemotherapy; poly (ADP-ribose) polymerases (PARP) inhibitors; Taxanes; Trabectedin; Pegylated-Liposomal-Doxorubicin (PLD)

Introduction

Ovarian cancer (OC) is the leading cause of gynecological cancer-related death and the fifth cause of cancer mortality in women in the Western Countries [1,2]. Most patients present at diagnosis with an advanced stage III and IV, which are managed by surgical optimal resection and systemic platinum-based chemotherapy. Although high response rate and significant improvement of median survival were observed, the plateau of survival rates has changed little in the last decade [3]. Only one third of patients can be cured with this approach and the majority will eventually relapse with a median progression-free survival of 18 months [4]. At present, five-year overall survival for stage III and IV OC accounts for approximately 45% [5,6].

In the last decade a major effort has been made to elucidate the development of OC, not only from a cell biology viewpoint (a cellular origin from Fallopian tube has been proposed) [5], but also from a genetic and biochemical perspective. The main contribution came from the discovery of breast cancer associated (*BRCA*) genes *BRCA1* and *BRCA2*. Germline mutations in *BRCA1* and *BRCA2* are responsible for 90% of hereditary OCs [6], the remaining 10% being due to mutations in mismatch-repair genes *MSH1* and *MSH2* [7]. Hereditary OCs collectively account for 10%-15% of all OC cases. Female carriers of *BRCA1* mutations have 16% to 60% lifetime risk of developing epithelial ovarian carcinoma, whereas female carriers of *BRCA2* mutations have a 16% to 27% risk [8,9]. *BRCA*-mutated tumors present peculiar epidemiological and clinical features, such as a higher incidence in specific populations (younger females, Jewish and Italian race), better chemosensitivity and outcome, with *BRCA2*-mutated carriers having the best prognosis [10].

Some 85%-90% of OCs is sporadic forms that very rarely harbor *BRCA1/2* mutations [11-13]. Surprisingly, a large proportion of sporadic OCs with wild-type *BRCA* genes displays a *BRCA*-like phenotype called "*BRCA*ness" [14-16]. The discovery of *BRCA*ness has important clinical implications because it refines stratification of OCs and provides the rationale for extending therapeutic options for *BRCA*-mutated OCs to a larger number of patients.

Investigating the genetic and clinical profile of the *BRCA* dysfunction is now crucial for understanding why *BRCA1/2* mutations and *BRCA*ness correlate with better chemosensitivity and outcome even if both conditions exhibit high-grade serous (HGS) histopathology and aggressive proliferation identical to the majority of sporadic, non *BRCA*-related OCs.

The present work reviews the molecular profile of *BRCA1/2*-mutated OCs and *BRCA*ness. Furthermore, evidences and controversies on their clinical behavior in terms of chemosensitivity and outcome are presented. To conclude, we discuss how the in-depth understanding of the molecular signature of *BRCA*-mutated OCs and *BRCA*ness is providing the rationale for new therapeutic strategies.

Genetic Profile of OC

BRCA1 and *BRCA2* in OC

The transmission of an autosomal dominant trait predisposing women to the development of breast cancer and OC was first reported in the early 1970s [17]. Twenty years later the genetic basis for this predisposition was established with the cloning of the genes *BRCA1* (located at chromosome 17q21) [18] and *BRCA2* (located at chromosome 13q12.3) [19]. *BRCA1* and *BRCA2* are tumor suppressor genes whose most notable function is to maintain genomic stability during meiosis and mitosis. Mutation of either *BRCA* gene in the germline predisposes to tumorigenesis, but is still compatible with normal phenotype. Cancer development depends upon a second *BRCA* mutation in somatic cells and *BRCA* loss of function. As typical of autosomal dominant inheritance, one mutation segregates in each

***Corresponding author:** Grazia Artioli, Department of Medical Science, Oncology and Hematology Unit, Mirano (VE)-Italy, Tel: +39-041-5794002; Fax: 0039.041.5794004; E-mail: grazia.artioli@yahoo.it

Received September 18, 2013; **Accepted** December 23, 2013; **Published** December 29, 2013

Citation: Artioli G, Borgato L, Ausoni S, Azzarello G (2013) Ovarian Cancer: *BRCA* Genetics Reveals Targets for New Therapies. J Genet Syndr Gene Ther 5: 209. doi:[10.4172/2157-7412.1000209](https://doi.org/10.4172/2157-7412.1000209)

Copyright: © 2013 Artioli G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

family, but rare examples of carriers with simultaneous mutation in *BRCA1* and *BRCA2* or two *BRCA2* mutations have been also described [20].

Absence of *BRCA* proteins results in an inefficient cell capacity to repair DNA damages produced by stress and genotoxic agents. This condition generates the common ground for the onset of other mutations and genomic instability. *BRCA1* and *BRCA2* control different stages of DNA repair and have complementary functions. This explains why loss of either *BRCA1* or *BRCA2* proteins is not fully compensated by the other. *BRCA1* senses DNA damage and repairs double-strand breaks (DSBs) and single strand breaks (SSBs). DSBs are repaired through homologous recombination (HR) and non-homologous end joining (NHEJ) pathways. HR repairs DNA breaks with high fidelity whereas NHEJ is imprecise and results in DNA deletions (exhaustively reviewed in [21,22]). Lack of *BRCA1* inhibits HR and may also impair NHEJ and SSB repair [23].

BRCA1 is also involved in other cell functions, such as activation of G1/S and G2/M checkpoints, regulation of telomere length and apoptosis [22] and mitotic spindle assembly [24].

In contrast to the multiple functions of *BRCA1*, *BRCA2* mediates the core mechanism of HR by loading other proteins to the sites of DSBs and stalled DNA replication forks. *BRCA2*-recruited partners include RAD51, PALB2 and *BRCA1* [25]. Abrogation of the *BRCA1*-RAD51-PALB2-*BRCA2* complex in vivo, though with intact *BRCA1* and *BRCA2* genes, impairs HR repair [26] and explains why mutations in *PALB2* and *RAD51* are also implicated in breast and OC predisposition [27,28].

Given that *BRCA1* and *BRCA2* are essential for a generic biological function such as DNA repair it is reasonable to wonder why mutations in *BRCA* genes preferentially induce gynecologic tumors. One theory is that each menstrual cycle produces an excess of free oxygen radicals followed by DNA damage and impaired repair in *BRCA*-mutated cells [22]. Alternatively, *BRCA1* might function as a regulator of estrogen receptor signaling and suppress estrogen-dependent transcriptional pathway related to mammary and ovarian cell proliferation, thus leading to tumorigenesis [29]. The site of mutations in *BRCA1* or *BRCA2* may also influence tropism, as suggested by the finding that breast and OC risk correlates with distinct clusters of mutations [30,31]. These results require further validation in a larger number of patients.

BRCAness in OC

BRCAness used to describe the *BRCA*-like phenotype in the absence of *BRCA1/2* mutations is a matter of genetic, molecular and clinical investigation. Based on the Cancer Genome Atlas study (TCGA) [32], *BRCAness* is the result of genetic and epigenetic aberrations. These include mainly hypermethylation of *BRCA1*; mutations or hypermethylation of other genes involved in various DNA repair pathways; mutations in genes encoding for regulators of *BRCA1* and *BRCA2*. Hypermethylation in CpG islands of *BRCA1* promoter inactivates the gene, as it was found in 11% cases of HGS-OCs of the 316 fully analyzed. *BRCA2* epigenetic silencing was never observed. Notably, epigenetic silencing of *BRCA1* was mutually exclusive with *BRCA1/2* mutations. In 3% of cases hypermethylation was found in *RAD51C*, a member of the RAD51 family.

Mutations and deletions were found in core members of the HR pathway, such as *RAD* genes, *PALB2*, *PTEN*, *ATR* and *ATM* and the Fanconi anemia cluster [32,33].

BRCAness due to mutations in proteins that regulate *BRCA1* and

BRCA2 functions were also described. An example is amplification of *EMSY*, an inhibitor of *BRCA2* that causes *BRCA2* silencing and genomic instability. Amplified *EMSY* were detected in 17% OCs and were associated to worse outcome [34].

BRCAness may be more prevalent than originally assumed. New susceptibility genes and pathways responsible for genomic instability (*TP53* and *FOXM1*), proliferation and apoptosis, (*PI3K/Akt/mTOR*, *RB* and *NOTCH*), are emerging. The potential of new sequencing technologies and the large cohorts of patients enrolled in clinical studies are likely to provide more reliable links between molecular data and phenotypic characterization of *BRCAness*.

Synthetic lethality

In 2005 Ashworth's and Helleday's laboratories first demonstrated that *BRCA1* and *BRCA2*-deficient cells were hypersensitive to pharmacological blockade of poly(ADP-ribose) polymerases (PARPs) [35,36]. PARPs are a family of enzymes involved in DNA repair, gene transcription, chromatin architecture and apoptosis [37]. The most abundant and well-studied member, PARP1, polymerizes poly(ADP-ribose) on substrate proteins to regulate repair of SSBs. PARP inhibition leads to accumulation of SSBs, followed by collapse of replication forks and subsequent formation of DSBs (reviewed in [38,39]). In normal cells DSBs are repaired via HR, but tumor cells lacking *BRCA1* or *BRCA2* cannot activate HR and do not tolerate inhibition of PARP. The synergistic cytotoxicity of PARP inhibitors and mutated *BRCA* genes was described as "synthetic lethality", namely a cell death produced by two enzymatic dysfunctions, one produced genetically and the other achieved pharmacologically. The finding that *BRCA1/2*-mutated cells can be killed using PARP inhibitors has opened a new era for antitumor therapies. Several PARP inhibitors have been produced and are currently under application in clinical trials (www.clinicaltrials.gov) [37,40].

Preclinical studies are now providing insights for a wider utilization of synthetic lethality as therapeutic strategy. Not only *BRCA1*- and *BRCA2*-mutated OCs are eligible, but also tumor variants displaying *BRCAness*, if we consider that cells lacking other proteins involved in HR may become sensitive to PARP inhibitors [32,41].

Clinical Findings

Platinum-based chemotherapy: the mainstay of treatment

A major clinical point in the management of OC is whether tumor variants (*BRCA*-mutated, *BRCAness*, sporadic) have common or distinct clinicopathological features, prognostic outcome and drug sensitivity. Hereditary and sporadic OCs harbor HGS histopathology and advanced stage at diagnosis. However, hereditary *BRCA*-mutated and *BRCAness* OCs have an improved overall survival compared to sporadic carcinomas [42]. It is difficult to determine whether such an improved prognosis is due to biological differences, greater chemosensitivity or both. A potential indolent clinical behavior due to a lower mitotic index was hypothesized. However, the majority of data agree that the determinant is the higher sensitivity to DSBs or to adducts generated by chemotherapeutic agents. Platinum compounds (cisplatin and carboplatin), are the mainstay treatment in ovarian cancer, demonstrating an antitumor activity as common alkylating agents that interact with DNA and form intra-strand adducts and inter-strand cross links [33,34,42].

The high sensitivity to platinum-based therapy is also maintained through multiple relapses of disease and is therefore essential for better

disease-free and overall survival in OCs. Several clinical studies, though mainly retrospective and based on a small number of patients, support this conclusion [42-46]. Cass et al. (2003) were the first who correlated platinum-based chemosensitivity to prolonged survival of hereditary vs. sporadic OCs (91 months vs. 54 months) [46]. This result has been confirmed in a recent study in which 22 patients with *BRCA1/2* mutations and *BRCA*ness with high family risk were compared to 44 sporadic epithelial OC patients treated with platinum-based therapy. *BRCA* group maintained better response rate either at first and second-line treatment with significant long time to first relapse (5 vs. 1.6 years, $p=.001$) and improved overall survival (8.4 years vs. 2.9, $p=.002$) [15].


In the standard platinum-based first line chemotherapy, platinum compounds are associated with mitotic spindle poisons, such as paclitaxel. The role of taxanes in *BRCA*-mutated OCs remains unclear and conflicting reports are still published [47]. An initial experimental study has demonstrated no sensitivity of *BRCA1*-mutated breast epithelial cell line HBL100 to taxanes [48], but recent clinical studies on *BRCA2* hormone sensitive breast [49,50] and prostate [51] cancer have provided preliminary evidences that sensitivity to taxanes (docetaxel) may be associated to *BRCA2* mutations. We also reported a case of complete remission in a *BRCA2*-mutated metastatic breast cancer treated with cisplatin and taxane (nab-paclitaxel) [52]. However,

there is no conclusive evidence of a link between *BRCA2* mutations and sensitivity to mitotic spindle poisons.

At present, clinical oncologists are struggling with two main concerns: platinum sensitivity of OCs and time point of relapse. The longer the interval, the longer the duration of response to be achieved by subsequent platinum treatment. Based upon this scheme three patient groups have been identified: platinum-sensitive relapsed disease (relapse >12 months after first line platinum delivery), refractory disease (relapse < 6 months), partially platinum-sensitive disease (relapse between 6-12 months). Patients with refractory and partially sensitive disease may benefit from the use of DNA-damaging agents that prolong platinum-free interval. Under the pressure of these agents cell clones with higher genomic instability proliferate and re-gain platinum-sensitivity [53]. This property helps designing a synergistic pharmacologic approach to the disease (Figure 1).

Beyond platinum-based chemotherapy: towards a personalized therapy?

Among alternative treatments in *BRCA1* and *BRCA2* OCs, PARP inhibitors, pegylated liposomal doxorubicin (PLD) and trabectedin have been considered either in preclinical and clinical settings. In *BRCA*-related OCs, PARP inhibitors represent the best example of



targeted translational research to date and a successful therapeutic application of the synthetic lethality. Phase I-II studies with single agent PARP inhibitor olaparib have shown dose-related response and acceptable safety profile in *BRCA1/2*-related OCs [54,55]. A recent phase II multicentre open-label non randomized study of olaparib in HGS-OC with or without *BRCA1/2* mutations, has shown better response in *BRCA*-mutated compared to non mutated patients (41% vs. 24%) [56]. Other PARP inhibitors, alone or in combination with chemotherapeutic or anti-angiogenetic agents, are under clinical trial in hereditary and sporadic OCs (www.clinicaltrials.gov).

A major advantage in the use of PARP inhibitors is that they can restore chemosensitivity in chemorefractory OCs. After relapse, patients treated with olaparib experienced disease progression, but then re-gained the potential to respond to platinum chemotherapy [57]. Interestingly, revertant phenotypes with restored *BRCA* function were identified in OC patients with *BRCA1/2* mutations. These cases accounted for 28% platinum-sensitive relapses and 46% platinum-resistant cases and were predictive for resistance to platinum and PARP-inhibition [58,59]. The mechanism of reversion is still unclear, but it can be hypothesized that under pressure of chemotherapies, somatic cells with high genomic instability accumulate additional *BRCA1/2* mutations that restore wild-type phenotype. PARP inhibitors could restore *BRCA1/2* function through genetic or epigenetic mechanisms [60]. Long-term PARP inhibition *per se* is also cause of tumor resistance, possibly through PARP gene mutations that alter interaction with inhibitors, or up-regulation of alternative DNA repair or cell proliferation pathways [61]. In summary, PARP inhibitors, the leading agents of synthetic lethality, are precious tools for killing tumor cells after the acquisition of resistance to previously employed therapies.

Targeting recurrent OCs benefits from other DNA-damaging agents as pegylated liposomal doxorubicin (PLD) that is a pegylated (polyethylene glycol coated) liposome-encapsulated form of doxorubicin that delivers higher drug concentration in cancer cells, resulting in a more favourable efficacy with less toxicity. Doxorubicin interferes with topoisomerase 2 and produces DNA breaks that cannot be repaired in cells lacking HR, thus causing cytotoxicity [62]. The efficacy of PLD in OC has been reported in a phase III study (MITO2) designed to compare the combination of carboplatin plus paclitaxel vs. carboplatin plus PLD in first line treatment. This study demonstrated similar progression-free survival, but better toxicity profile, for carboplatin plus PLD [63] and similar data were provided for platinum sensitive OCs. In platinum-resistant relapsed OC, PLD used alone provide better outcome over other single chemotherapeutic agents [64].

A few retrospective studies have demonstrated that *BRCA* mutations are predictor of improved outcome in relapsed hereditary OCs treated with PLD [62,65,66]. In particular, family history or *BRCA1/2* mutations predict better outcome as compared to sporadic OCs [62], both in median time to treatment failure (15.8 months vs. 8.1 months, $p=0.009$) and overall survival (56.8 months vs. 22.6 months, $p=0.002$) [65], providing further a compelling rationale for a more personalized treatment based on the *BRCA* status. A randomized phase II study, involving 97 patients with partially platinum-sensitive hereditary OCs, compared olaparib vs. PLD obtaining a satisfactory, though non-statistically significant, median progression free survival [67].

Trabectedin, an anti-tumor compound originally extracted by the marine organism *Tunicate Ecteinascidia*, and now synthetically

produced for pharmacological purposes, is another promising option for OCs resistant to previous therapies [68]. Trabectedin has a unique mechanism of action based on interaction with the minor groove of the DNA double helix generating adducts that bend DNA and induce DSBs, it affects gene transcription and DNA repair pathways, resulting in G2-M cell cycle arrest and ultimately apoptosis [69]. Trabectedin cytotoxicity is determined by the functional nucleotide excision repair (NER) and a deficient homologous recombination repair (HRR) machinery. Consequently, trabectedin shows decreased activity (from 2- to 8-fold) in NER-deficient cell lines, while cells deficient in HRR are approximately 100 times more sensitive to the drug [70,71].

Trabectedin is demonstrated to be active in breast, ovarian, non-small cell lung cancers, melanoma and sarcoma and several reports showed that it could be safely combined with other agents such as gemcitabine and PLD [72-74]. Monk reported a phase III study on recurrent, partially platinum-sensitive OCs treated with trabectedin plus PLD. Combined agents revealed better platinum-free survival over PLD alone (7.3 versus 5.8 months; $p=0.019$) with 46% vs. 21% reduced risk of progressive disease [75]. Taking into account these results and the remarkable reviewed data on survival (23 months, 41% reduction in the risk of death) [76], trabectedin in combination with PLD received approval for the treatment of recurrent partially-platinum sensitive OC.

Based on this strong preclinical rationale and the previous results of phase III study in unselected OCs, a Phase II multicentre study (MITO 15) is actually ongoing to evaluate the activity of trabectedin in *BRCA1/2* mutation carriers or *BRCA*-ness phenotype (clinicaltrials.gov).

Concluding Remarks and Future Directions

OC due to *BRCA* dysfunction depends upon a complex genetic profile, whose common determinant is the lack of efficient DNA repair, the disruption of genomic stability and consequent tumorigenesis. Genetic and epigenetic abnormalities identified three different genotypes, *BRCA1*- and *BRCA2*-mutated OCs and *BRCA*ness. The mutation spectrum reveals that 20% of HGS-OC have germline or somatic mutations in *BRCA1/2*, 11% have lost *BRCA1* expression through hypermethylation and that *BRCA1* is inactivated by mutually exclusive genomic and epigenetic mechanisms. On the other hand, *BRCA*ness, which should be considered separately from non *BRCA*-related cases, lack a complete genotypic profile.

At present, it is difficult to classify hereditary or sporadic OCs based upon genetic counseling and family history, due to selection bias. Thus, a detailed molecular characterization of the different OC genotypes is needed. In addition, protein profiling of *BRCA*-related tumors and *BRCA*ness would help understanding how gene transcription, post-translational modifications, proteins dynamic, signaling and metabolic pathways, change under the pressure of gene mutations and genomic instability.

Genomics

Laboratory tests to determine gene mutations and promoter hypermethylation are still difficult to apply on a large scale, and extremely expensive. However, these data should be made available to clinicians before treatment decision, particularly to distinguish *BRCA*ness from other OC variants and to aid molecular subtype stratification of *BRCA*-related OCs. In addition, some peculiar genomic features, such as the methylation state of genes responsible for *BRCA*ness should be monitored over time, since they seem to undergo changes during cell life [77].

Proteomics

Protein profiling of OCs is equally important because proteins are the functional effectors of gene expression and because proteomic analysis offers the opportunity for finding new biomarkers of the disease and new molecular targets for more personalized therapy. A proteomic profile that distinguishes *BRCA*-related tumors and *BRCAness* from the other HGS-OC variants is still lacking. To gain insight into this issue, protein microarray and tissue immunohistochemistry were used to detect proteins involved in homologous recombination (*FANCD2*, *BRCA1*, *PARP*, *H2AX*, *ATM*, *PTEN* and *p53*) over a cohort of 186 patients with sporadic OC. This study identified a *BRCAness* protein profile that is not associated with *BRCA1* and linked triple positive *FANCD2*+/*PARP*+/*P53*+ patients with very early recurrence of the disease [78].

Over the last decade, high-throughput technologies have allowed identification of novel biomarkers in serum, ascites and tissue samples derived from OC patients and OC cell lines on a large scale [79]. Since OC represents a complex and heterogeneous disease, it is unlikely that a single biomarker provides specificity and sensitivity for all OC types. Thus, integrative proteomics for the identification of biomarkers of *BRCA*-related tumors and *BRCAness* are promising venues, but should be designed carefully taking into account that the bottleneck of this approach is clinical validation in a subpopulation affected by a rare tumor.

Acknowledgments

We apologize to all authors whose contributions were not cited due to space limitations. We are grateful to all patients of the Department of Medical Sciences-Oncology and Hematology Unit of Mirano Hospital, who were enrolled in the clinical studies cited in this article. The text revision of mother language expert Martina Boscaro is greatly acknowledged.

References

- Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. *CA Cancer J Clin* 59: 225-249.
- Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. *CA Cancer J Clin* 60: 277-300.
- Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. *Nat Rev Cancer* 11: 719-725.
- Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. *Lancet* 374: 1371-1382.
- Levanon K, Crum C, Drapkin R (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. *J Clin Oncol* 26: 5284-5293.
- Pennington KP, Swisher EM (2012) Hereditary ovarian cancer: beyond the usual suspects. *Gynecol Oncol* 124: 347-353.
- Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, et al. (2005) *BRCA1* and *BRCA2* mutations account for a large proportion of ovarian carcinoma cases. *Cancer* 104: 2807-2816.
- Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, et al. (2002) Cancer risk estimates for *BRCA1* mutation carriers identified in a risk evaluation program. *J Natl Cancer Inst* 94: 1365-1372.
- King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group (2003) Breast and ovarian cancer risks due to inherited mutations in *BRCA1* and *BRCA2*. *Science* 302: 643-646.
- Yang D, Khan S, Sun Y, Hess K, Shmulevich I, et al. (2011) Association of *BRCA1* and *BRCA2* mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. *JAMA* 306: 1557-1565.
- Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, et al. (1996) Somatic and germline mutations of the *BRCA2* gene in sporadic ovarian cancer. *Cancer Res* 56: 3622-3625.
- Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE (2002) Frequency of *BRCA1* dysfunction in ovarian cancer. *J Natl Cancer Inst* 94: 61-67.
- Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, et al. (1995) Somatic mutations in the *BRCA1* gene in sporadic ovarian tumours. *Nat Genet* 9: 439-443.
- Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. *Nat Rev Cancer* 4: 814-819.
- Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, et al. (2008) "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with *BRCA1* and *BRCA2* mutations. *J Clin Oncol* 26: 5530-5536.
- Rigakos G, Razis E (2012) BRCAness: finding the Achilles heel in ovarian cancer. *Oncologist* 17: 956-962.
- Lynch HT, Guirgis HA, Albert S, Brennan M, Lynch J, et al. (1974) Familial association of carcinoma of the breast and ovary. *Surg Gynecol Obstet* 138: 717-724.
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science* 266: 66-71.
- Wooster R, Bignell G, Lancaster J, Swift S, Seal S, et al. (1995) Identification of the breast cancer susceptibility gene *BRCA2*. *Nature* 378: 789-792.
- Heidemann S, Fischer C, Engel C, Fischer B, Harder L, et al. (2012) Double heterozygosity for mutations in *BRCA1* and *BRCA2* in German breast cancer patients: implications on test strategies and clinical management. *Breast Cancer Res Treat* 134: 1229-1239.
- Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) *Brca1* controls homology-directed DNA repair. *Mol Cell* 4: 511-518.
- Roy R, Chun J, Powell SN (2011) *BRCA1* and *BRCA2*: different roles in a common pathway of genome protection. *Nat Rev Cancer* 12: 68-78.
- Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M (2004) Genetic steps of mammalian homologous repair with distinct mutagenic consequences. *Mol Cell Biol* 24: 9305-9316.
- Joukov V, Groen AC, Prokhorova T, Gerson R, White E, et al. (2006) The *BRCA1/BARD1* heterodimer modulates ran-dependent mitotic spindle assembly. *Cell* 127: 539-552.
- Holloman WK (2011) Unraveling the mechanism of *BRCA2* in homologous recombination. *Nat Struct Mol Biol* 18: 748-754.
- Sy SM, Huen MS, Chen J (2009) *PALB2* is an integral component of the *BRCA* complex required for homologous recombination repair. *Proc Natl Acad Sci U S A* 106: 7155-7160.
- Simpson S (2007) *PALB2*-new breast-cancer susceptibility gene. *Lancet Oncol* 8: 105.
- Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, et al. (2010) Germline mutations in breast and ovarian cancer pedigrees establish *RAD51C* as a human cancer susceptibility gene. *Nat Genet* 42: 410-414.
- Fan S, Wang J, Yuan R, Ma Y, Meng Q, et al. (1999) *BRCA1* inhibition of estrogen receptor signaling in transfected cells. *Science* 284: 1354-1356.
- Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, et al. (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the *BRCA2* gene. *Nat Genet* 15: 103-105.
- Thompson D, Easton D; Breast Cancer Linkage Consortium (2001) Variation in cancer risks, by mutation position, in *BRCA2* mutation carriers. *Am J Hum Genet* 68: 410-419.
- Bell D, Berchuck A, Birrer M, Chien J, Cramer D, et al. (2011) Integrated genomic analyses of ovarian carcinoma. *Nature* 474: 609-615.
- Taniguchi T, Tischkowitz M, Ameiziane N, Hodgson SV, Mathew CG, et al. (2003) Disruption of the Fanconi anemia-*BRCA* pathway in cisplatin-sensitive ovarian tumors. *Nat Med* 9: 568-574.
- Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, et al. (2003) EMSY links the *BRCA2* pathway to sporadic breast and ovarian cancer. *Cell* 115: 523-535.
- Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. (2005) Targeting

- the DNA repair defect in *BRCA* mutant cells as a therapeutic strategy. *Nature* 434: 917-921.
36. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of *BRCA2*-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 434: 913-917.
 37. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from *BRCA* mutation carriers. *N Engl J Med* 361: 123-134.
 38. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. *Nat Rev Cancer* 10: 293-301.
 39. Helleday T (2011) The underlying mechanism for the PARP and *BRCA* synthetic lethality: clearing up the misunderstandings. *Mol Oncol* 5: 387-393.
 40. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: a proof-of-concept trial. *Lancet* 376: 235-244.
 41. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, et al. (2010) Gene expression profile of *BRCA*ness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. *J Clin Oncol* 28: 3555-3561.
 42. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, et al. (2002) Effect of *BRCA* mutations on the length of survival in epithelial ovarian tumors. *J Clin Oncol* 20: 463-466.
 43. Boyd J, Sonoda Y, Federici MG, Bogomolny F, Rhei E, et al. (2000) Clinicopathologic features of *BRCA*-linked and sporadic ovarian cancer. *JAMA* 283: 2260-2265.
 44. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, et al. (2008) Effect of *BRCA1/2* mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer *J Clin Oncol* 26: 20-25.
 45. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, et al. (2011) Chemosensitivity and outcome of *BRCA1*- and *BRCA2*-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients *Ann Oncol* 22: 1346-1352.
 46. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, et al. (2003) Improved survival in women with *BRCA*-associated ovarian carcinoma. *Cancer* 97: 2187-2195.
 47. Chalasani P, Livingston R (2013) Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. *Oncologist* 18: 909-916.
 48. Lafarge S, Sylvain V, Ferrara M, Bignon YJ (2001) Inhibition of *BRCA1* leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. *Oncogene* 20: 6597-6606.
 49. Kriege M, Jager A, Hoening MJ, Huijskens E, Blom J, et al. (2012) The efficacy of taxane chemotherapy for metastatic breast cancer in *BRCA1* and *BRCA2* mutation carriers. *Cancer* 118: 899-907.
 50. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, et al. (2001) Decreased expression of *BRCA2* mRNA predicts favorable response to docetaxel in breast cancer. *Int J Cancer* 95: 255-259.
 51. Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, et al. (2012) Germline *BRCA* mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. *BJU Int* 109: 713-719.
 52. Artioli G, Azzarello G, Meggiolaro F, Wabersich J, Borgato L, et al. (2013) Case Report: Complete Clinical Response of a Young Patient with a *BRCA2* Positive Metastatic Breast Cancer. *Advances in Breast Cancer Research* 2: 56-59.
 53. See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, et al. (2005) Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. *Int J Gynecol Cancer* 15: 209-216.
 54. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* 376: 245-251.
 55. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, et al. (2010) Poly(ADP-ribose) polymerase inhibition: frequent durable responses in *BRCA* carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol* 28: 2512-2519.
 56. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, et al. (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *The Lancet oncology* 12: 852-861.
 57. Ang J, Yap TA, Fong P, Carden CP, Tan DS, et al. (2010) Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with *BRCA1/2*-deficient ovarian cancer (BDOC). 28: 5041.
 58. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, et al. (2008) Secondary mutations as a mechanism of cisplatin resistance in *BRCA2*-mutated cancers. *Nature* 451: 1116-1120.
 59. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, et al. (2008) Resistance to therapy caused by intragenic deletion in *BRCA2*. *Nature* 451: 1111-1115.
 60. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, et al. (2011) Secondary somatic mutations restoring *BRCA1/2* predict chemotherapy resistance in hereditary ovarian carcinomas. *J Clin Oncol* 29: 3008-3015.
 61. Yap TA, Sandhu SK, Carden CP, de Bono JS (2011) Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. *CA Cancer J Clin* 61: 31-49.
 62. Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, et al. (2011) *BRCA* mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. *Mol Cancer Ther* 10: 2000-2007.
 63. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebiski V, Heywood M, et al. (2010) Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. *J Clin Oncol* 28: 3323-3329.
 64. Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J (2013) Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. *Cochrane Database Syst Rev* 7: CD006910.
 65. Nicoletto MO, Bertorelle R, Borgato L, De Salvo GL, Artioli G, et al. (2009) Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer *Int J Gynecol Cancer* 19: 1022-1028.
 66. Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, et al. (2011) A high response rate to liposomal doxorubicin is seen among women with *BRCA* mutations treated for recurrent epithelial ovarian cancer. *Gynecol Oncol* 123: 486-491.
 67. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, et al. (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with *BRCA1* or *BRCA2* mutations and recurrent ovarian cancer. *J Clin Oncol* 30: 372-379.
 68. Rinehart KL (2000) Antitumor compounds from tunicates. *Med Res Rev* 20: 1-27.
 69. David-Cordonnier MH, Gajate C, Olmea O, Laine W, de la Iglesia-Vicente J, et al. (2005) DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. *Chem Biol* 12: 1201-1210.
 70. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S (2006) Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. *Cancer Res* 66: 8155-8162.
 71. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, et al. (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. *Nat Med* 7: 961-966.
 72. von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, et al. (2008) A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. *Ann Oncol* 19: 1802-1809.
 73. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, et al. (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. *J Clin Oncol* 23: 1867-1874.
 74. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, et al. (2007) A Phase II study of trabectedin single agent in patients with recurrent ovarian

- cancer previously treated with platinum-based regimens. Br J Cancer 97: 1618-1624.
75. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, et al. (2010) Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. Eur J Cancer 28: 3107-3114.
76. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, et al. (2011) Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 22: 39-48.
77. Lord CJ, Ashworth A (2013) Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 19: 1381-1388.
78. Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, et al. (2012) BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One 7: e30042.
79. Leung F, Diamandis EP, Kulasingam V (2012) From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. Biomark Med 6: 613-625.

This article was originally published in a special issue, **Cancer Genetics** handled by Editor(s). Dr. Ahmed M Malki, Alexandria University, Egypt